On April 20, 2010, Hoffman LaRoche, in collaboration with Health Canada issued a report describing dose-dependent abnormal electrical activity or conduction in the heart (specifically prolongations of QT and PR intervals) in healthy volunteers.
They suggested that caution be taken in patients with known QT prolongation abnormalities or those taking other medications known to prolong the QT interval and the administration of Invirase.
Physicians should order baseline electrocardiograms (ECGs) for patients for whom they wish to prescribe Invirase. In addition, patients on Invirase experiencing heart palpitations should contact their physician.
For more information: Click here to view the Health Canada advisory